Jupiter Topco LLC Takes Position in Savara Inc. $SVRA

Jupiter Topco LLC acquired a new position in shares of Savara Inc. (NASDAQ:SVRA) in the second quarter, HoldingsChannel.com reports. The institutional investor acquired 466,611 shares of the company’s stock, valued at approximately $2,875,000.

Several other institutional investors have also recently modified their holdings of the stock. ADAR1 Capital Management LLC purchased a new stake in Savara in the 2nd quarter valued at approximately $8,645,000. Legal & General Group Plc purchased a new position in Savara during the second quarter worth $351,000. The Manufacturers Life Insurance Company acquired a new position in shares of Savara in the second quarter worth $430,000. Spruce Street Capital LP acquired a new position in shares of Savara in the second quarter worth $21,267,868. Finally, Algert Global LLC lifted its position in shares of Savara by 53.7% in the second quarter. Algert Global LLC now owns 1,329,259 shares of the company’s stock valued at $8,188,000 after acquiring an additional 464,645 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Wall Street Zen cut Savara from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $10.14.

Savara Trading Up 2.1%

NASDAQ SVRA opened at $5.46 on Thursday. Savara Inc. has a 12 month low of $3.32 and a 12 month high of $7.01. The company has a 50-day moving average of $5.68 and a 200-day moving average of $5.48. The company has a debt-to-equity ratio of 0.21, a current ratio of 10.13 and a quick ratio of 10.13. The company has a market cap of $1.12 billion, a P/E ratio of -9.41 and a beta of 0.25.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). As a group, equities analysts predict that Savara Inc. will post -0.62 earnings per share for the current year.

Savara Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.